4-amino-2-diethylaminomethylphenol dihydrochloride | 6297-14-9

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-2-diethylaminomethylphenol dihydrochloride
• 英文别名: 4-Amino-alpha-diethylamino-o-cresol, dihydrochloride；4-amino-2-(diethylaminomethyl)phenol;hydrochloride
• CAS: 6297-14-9
• 化学式: C₁₁H₁₈N₂O*ClH
• 分子量: 230.738
• InChiKey: KWNAKIVTTHIRJV-UHFFFAOYSA-N

物化性质

• 熔点：
  215-218 °C (dec.)(lit.)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  2.24
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  49.5
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S24/25
• 危险类别码：
  R22,R37/38,R41
• WGK Germany：
  3
• 海关编码：
  2922299090

SDS

Name:	4-Amino-Alpha-Diethylamino-Ortho-Cresol Dihydrochloride 97% Material Safety Data Sheet
Synonym:	None known
CAS:	6297-14-9

Section 1 - Chemical Product MSDS Name:4-Amino-Alpha-Diethylamino-Ortho-Cresol Dihydrochloride 97% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6297-14-9	4-Amino-Alpha-Diethylamino-Ortho-Creso	97	228-568-7

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6297-14-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: slightly brown
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 215.00 - 218.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H18N2O.2HCl
Molecular Weight: 267.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6297-14-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Amino-Alpha-Diethylamino-Ortho-Cresol Dihydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6297-14-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6297-14-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6297-14-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-amino-2-diethylaminomethylphenol dihydrochloride 、 11-chloro-10H-indolo[3,2-b]quinoline 以 乙二醇乙醚 为溶剂， 反应 6.0h， 以67%的产率得到4-(10H-Indolo<3,2-b>chinolin-11-yl)amino-2-diethylaminomethyl-phenol-dihydrochlorid
  参考文献：
  名称：

  Gorlitzer; Stockmann; Walter, Pharmazie, 1994, vol. 49, # 4, p. 231 - 235

  摘要：

  DOI：
• 作为产物：
  描述：

  4-乙酰胺-2-二乙氨甲基苯酚 在 盐酸 作用下， 以 水 为溶剂， 反应 2.0h， 以88%的产率得到4-amino-2-diethylaminomethylphenol dihydrochloride
  参考文献：
  名称：

  具有曼尼希碱基侧链的抗疟原虫吡啶并[1,2-a]苯并咪唑衍生物：合成，药理学评估和活性代谢物捕集研究。

  摘要：

  合成了一系列新型的带有曼尼希碱基侧链的吡啶并[1,2-a]苯并咪唑及其代谢物，并对其在小鼠中的体外抗疟原虫活性，微粒体代谢稳定性，反应性代谢产物（RM）形成和体内抗疟疾功效进行了评估。模型。在伯氏疟原虫感染的小鼠中口服4×50 mg / kg的一种衍生物可将寄生虫病降低95％，平均存活期为治疗后16天。这些衍生物的体内功效可能是其活性代谢产物的结果，其中两种代谢产物显示出对氯喹敏感和多药耐药性恶性疟原虫（P. falciparum）菌株有效的体外抗疟原虫活性。观察到所有< 在肝微粒体中孵育30分钟后，剩余40％的母体化合物。RM捕集研究仅在带有4-氨基苯酚部分的衍生物中检测到了谷胱甘肽加合物，其片段签名表明该缀合发生在曼尼希碱基侧链的苯环上。与氨二喹（AQ）一样，交换4-羟基和曼尼希碱基侧基的位置或用氟取代4-羟基似乎阻止了AQ-like衍生物的生物活化，尽管这是以抗疟原虫活性为代价的，这大大降低了抗疟原虫的活性。

  DOI：

  10.1021/acsinfecdis.8b00279

文献信息

• Discovery of a potent non-oxime reactivator of nerve agent inhibited human acetylcholinesterase
  作者：Martijn Constantijn de Koning、Gabriele Horn、Franz Worek、Marco van Grol

  DOI：10.1016/j.ejmech.2018.08.016

  日期：2018.9

  compounds that could reactivate OP-inhibited AChE. Recently, a number of non-oxime compounds was discovered in which the 4-amino-2-((diethylamino)methyl)phenol (ADOC) motif proved to be able to reactivate OP-inhibited AChE to some extent. In this paper several structural derivatives of ADOC were synthesized and screened for their ability to reactivate human AChE (hAChE) inhibited by the nerve agents

  有机磷（OP）化合物（例如神经毒剂）通过在酶活性部位的关键丝氨酸残基进行共价磷酸化来抑制乙酰胆碱酯酶（AChE），从而导致严重的症状并最终导致死亡。目前通过给予某些肟化合物来治疗OP中毒。目前获得的肟通过释放磷酸化的丝氨酸来重新激活OP抑制的AChE。最近对新型活化剂的研究主要致力于设计，合成和评估基于肟的新型化合物，这些化合物致力于克服一些主要局限性，例如其固有毒性，阻碍大脑组织渗透的永久电荷以及无法有效活化所有活性物质。类型的神经毒剂抑制了AChEs。然而，在超过六十年的研究中，仅取得了有限的成功，这表明需要能够重新激活OP抑制的AChE的其他类别的化合物。最近，发现了许多非肟化合物，其中4-氨基-2-（（二乙基氨基）甲基）苯酚（ADOC）母题被证明能够在一定程度上重新激活OP抑制的AChE。在本文中，合成了ADOC的几种结构衍生物，并筛选了它们重新激活被神经毒剂VX，沙林，塔宾，环沙
• Synthesis and evaluation of chromone-2-carboxamide derivatives as cytotoxic agents and 5-lipoxygenase inhibitors
  作者：Fatima Bousejra-ElGarah、Barbora Lajoie、Jean-Pierre Souchard、Geneviève Baziard、Jalloul Bouajila、Salomé El Hage

  DOI：10.1007/s00044-016-1691-y

  日期：2016.11

  potency to inhibit the proliferation of breast (MCF-7), ovarian (OVCAR and IGROV), and colon (HCT-116) cancer cell lines, was evaluated in vitro using the MTT assay. Among these compounds, 13 showed promising cytotoxic activity against at least one cancer cell line with IC50 in the range 0.9–10 μM. Our compounds were also screened for their anti-inflammatory activity as putative inhibitors of 5-lipoxygenase

  在本研究中，我们制备了一系列具有多种酰胺侧链的21色酮羧酰胺衍生物。使用MTT分析法在体外评估了它们抑制乳腺癌（MCF-7），卵巢癌（OVCAR和IGROV）和结肠癌（HCT-116）癌细胞系增殖的能力。在这些化合物中，有13种显示出对至少一种癌细胞的有希望的细胞毒活性，其IC 50为0.9-10μM。还筛选了我们的化合物作为5-脂氧合酶的抑制剂的抗炎活性。对色酮羧酰胺衍生物的结构-活性关系研究表明，色酮核（R 1）或丙基上存在6-氟取代基酰胺侧链上的3-乙基苯基（R 2）对细胞毒性活性有积极影响。就抗炎活性而言，亲水性色酮羧酰胺衍生物表现出更大的5-脂氧合酶抑制作用。色酮羧酰胺的理化性质符合药物开发过程的一般要求，配体效率值可进一步优化化合物结构。4b作为线索。
• (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
  申请人：——

  公开号：US20020028828A1

  公开（公告）日：2002-03-07

  The present invention relates to (2-oxindol-3-ylidenyl)acetic acid derivatives which modulate the activity of protein kinases and are therefore useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及(2-噁因醌-3-基亚基)乙酸衍生物，可调节蛋白激酶的活性，因此在预防和治疗蛋白激酶相关的细胞疾病如癌症方面具有用处。
• Anti-inflammatory 3-(substituted-amino)-2,1-benzisothiazoles
  申请人：Sterling Drug Inc.

  公开号：US04112105A1

  公开（公告）日：1978-09-05

  3-(Substituted-amino)-2,1,-benzisothiazoles useful as anti-inflammatory agents are prepared by reductive cyclization of appropriately substituted 2-nitrothiobenzamides or by reaction of 3-chloro-2,1-benzisothiazoles with suitably substituted amines.

  通过适当取代的2-硝基硫代苯甲酰胺的还原环化或将3-氯-2,1-苯并异噻唑与适当取代的胺反应，制备用作抗炎药物的3-(取代氨基)-2,1-苯并异噻唑。
• Insights into the structural patterns of the antileishmanial activity of bi- and tricyclic N-heterocycles
  作者：Lizzi Herrera、David E. Stephens、Abigail D'Avila、Kathryn G. George、Hadi Arman、Yu Zhang、George Perry、Ricardo Lleonart、Oleg V. Larionov、Patricia L. Fernández

  DOI：10.1039/c6ob01149g

  日期：——

  various structural patterns in a series of novel bi- and tricyclic N-heterocycles on the activity against Leishmania major and Leishmania panamensis has been studied and compounds that are active in the low micromolar region have been identified. Both quinolines and tetrahydrooxazinoindoles (TOI) proved to have significant antileishmanial activities, while substituted indoles were inactive. We have also

  研究了一系列新型双环和三环 N-杂环中的各种结构模式对针对大型利什曼原虫和巴拿马利什曼原虫的活性的影响，并鉴定了在低微摩尔区域具有活性的化合物。喹啉和四氢恶嗪吲哚 (TOI) 均被证明具有显着的抗利什曼活性，而取代的吲哚则无活性。我们还表明，氯喹类似物通过调节巨噬细胞活化来诱导利什曼原虫死亡。